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The association of the major histocompatibility complex (MHC) with SLE is well established yet the causal variants
arising from this region remain to be identified, largely due to inadequate study design and the strong linkage
disequilibrium demonstrated by genes across this locus. The majority of studies thus far have identified strong
association with classical class II alleles, in particular HLA-DRB1*0301 and HLA-DRB1*1501. Additional associations have
been reported with class III alleles; specifically, complement C4 null alleles and a tumor necrosis factor promoter SNP
(TNF-308G/A). However, the relative effects of these class II and class III variants have not been determined. We have
thus used a family-based approach to map association signals across the MHC class II and class III regions in a cohort of
314 complete United Kingdom Caucasian SLE trios by typing tagging SNPs together with classical typing of the HLA-
DRB1 locus. Using TDT and conditional regression analyses, we have demonstrated the presence of two distinct and
independent association signals in SLE: HLA-DRB1*0301 (nominal p ¼ 4.9 3 10
 8, permuted p , 0.0001, OR ¼ 2.3) and
the T allele of SNP rs419788 (nominal p¼4.3310
 8, permuted p , 0.0001, OR¼2.0) in intron 6 of the class III region
gene SKIV2L. Assessment of genotypic risk demonstrates a likely dominant model of inheritance for HLA-DRB1*0301,
while rs419788-T confers susceptibility in an additive manner. Furthermore, by comparing transmitted and
untransmitted parental chromosomes, we have delimited our class II signal to a 180 kb region encompassing the
alleles HLA-DRB1*0301-HLA-DQA1*0501-HLA-DQB1*0201 alone. Our class III signal importantly excludes independent
association at the TNF promoter polymorphism, TNF-308G/A, in our SLE cohort and provides a potentially novel locus
for future genetic and functional studies.
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Introduction
Since the early 1970s, the human major histocompatibility
complex (MHC) has been shown to be associated with a
number of autoimmune, inﬂammatory, and infectious dis-
eases, and it continues to be the focus of intense research [1].
The recently deﬁned extended MHC (xMHC) encompasses
7.6 Mb of genome on 6p21.3 and is divided into ﬁve
subregions from telomere to centromere: extended class I,
classical class I, classical class III, classical class II, and
extended class II. In addition, the MHC contains two
hypervariable regions, the RCCX module in class III (span-
ning complement C4) and the HLA-DRB genes in class II, that
both exhibit copy number polymorphism. Examination of the
sequence across the extended MHC reveals the presence of
421 genes, and over 252 (60%) are thought to be expressed
[2]. Around 40% of genes expressed within the classical MHC
encode proteins with putative immunomodulatory function
[3]. The classical class I and class II loci encode the human
leucocyte antigen (HLA) proteins involved in antigen
presentation to T cells, initiating the adaptive immune
response. The class III region contains the greatest density
of genes in the genome (58 expressed genes), which are often
found in functionally related clusters [2].
A major obstacle in the identiﬁcation of disease-speciﬁc
causal variants within the MHC has been the strong linkage
disequilibrium (LD) exhibited by certain alleles in this region,
resulting in the existence of long-range, conserved, extended
haplotypes [4], also known as ancestral haplotypes [5],
sometimes spanning more than 2 Mb [6]. Thus, for many
MHC-associated diseases, it has only been possible to delimit
association signals to a particular extended haplotype or
segment of one.
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lian Inheritance in Man 152700, http://www.ncbi.nlm.nih.gov/
sites/entrez?db¼OMIM&TabCmd¼Limits]) is a chronic, multi-
system autoimmune disease affecting young women ten times
more commonly than men. The worldwide prevalence of SLE
is estimated at between 12 and 124 cases per 100,000
individuals [7]. SLE is characterized by the presence of
pathogenic autoantibodies to nuclear and cell-surface anti-
gens that show afﬁnity maturation. The consequent immune
complexes deposit in tissues, causing inﬂammation and
damage. It is well established that there is a complex genetic
component to lupus aetiology, with hormonal and environ-
mental inﬂuences also contributing to disease susceptibility
[8,9].
The MHC has been the most consistently conﬁrmed genetic
risk factor for SLE, and multiple different genes within the
region have been signiﬁcantly implicated with disease
susceptibility. For example, hereditary and acquired deﬁcien-
cies of the early classical complement component C4, located
within the MHC class III locus, leads to a lupus-like syndrome.
A role for another class III gene, tumour necrosis factor alpha
(TNF), in SLE was suggested following the observation that
the lupus-prone New Zealand F1 mouse hybrid exhibits
constitutively low TNF expression [10]. Recently, the develop-
ment of antinuclear antibodies in patients treated with TNF
antagonists has also stimulated interest in the possible role of
TNF in SLE [11–13]. Murine and human candidate gene
studies, together with genome-wide linkage screens, provide
further support that multiple genetic loci, including the
mouse MHC complex H2 and the human MHC locus,
contribute to disease susceptibility [14–17].
It should be noted that the human MHC was ﬁrst associated
with SLE in 1971, when studies demonstrated that lupus
probands were enriched for the class I alleles HL-A8 (now
known as HLA-B8) and HLA-W15 (now known as HLA-B15)
when compared with healthy controls [18,19]. Further case
control association studies were small, performed in ethni-
cally diverse populations, and tested only a small number of
the classical HLA and complement C4 alleles. The most
consistent ﬁndings reported to date are associations with the
class II alleles HLA-DR2 (DRB1*1501)a n dHLA-DR3
(DRB1*0301) and their respective haplotypes in Caucasian
populations. The complement C4A null allele (C4A*Q0) has
shown inconsistent association with lupus in a number of
studies—a situation that may reﬂect genetic heterogeneity in
disease susceptibility [20–23]. In addition, a recent study has
demonstrated that low C4A copy number is a risk factor for
lupus in a European American cohort [24]. However, the C4A
null allele lies on the lupus-associated DR3 ‘‘autoimmune’’
extended haplotype (AH8.1), which exhibits extremely strong
LD [6]. It therefore remains to be deﬁnitively established
whether this locus constitutes a distinct susceptibility allele to
that of the class II association or is merely in LD with it.
Similarly, certain TNF promoter polymorphisms, including
the much-studied SNP TNF-308G/A, have shown association
with SLE; but again, many of these variants are carried on the
highly conserved 8.1 ancestral haplotype, thus restricting
interpretation of these data.
In 2002, a family-based study employing microsatellites as
surrogate markers for HLA-DRB1 haplotypes in Caucasian
lupus families demonstrated association with DR3-, DR2-, and
DR8 (DRB1*0801)-containing haplotypes. In that study,
Graham and colleagues reported that, taking advantage of
recombinant chromosomes, the disease risk region could be
limited to a 1 Mb region encompassing classical class II and
class III [25].
We have performed a medium resolution association
mapping study of the MHC in lupus families, utilizing a
combination of SNPs and four-digit typing at the HLA-DRB1
locus in order to anchor haplotypes. Sixty-eight SNPs were
successfully genotyped across a 2.4 Mb region of the MHC,
from the class I locus KIAA1949 to the class II gene HLA-
DPB2, in 314 UK Caucasian SLE trios. We used these data to
perform a family-based association study in an attempt to
distinguish the relative effects of the class II and class III
regions of the MHC in lupus susceptibility. In addition, we
employed the long-range haplotype test to search for the
presence of high-frequency, extended haplotypes indicative
of recent positive selection [26]. We have also used family-
based and case-control strategies to examine genotypic risk at
HLA-DRB1 and rs419788.
Results
Association Testing of HLA-DRB1 and MHC Region SNPs
In order to deﬁne the causal variation within the MHC
region, we typed 314 complete SLE trios for the HLA-DRB1
gene as well as for 86 SNPs across a 2.4 Mb region
encompassing the HLA class I locus HLA-B to HLA-DPB2.
High-quality genotype data was obtained for HLA-DRB1 and
68 MHC SNPs (see Table S1 for quality control data).
Association testing of the HLA-DRB1 gene revealed a
signiﬁcant association with HLA-DRB1*0301 (nominal p ¼
4.9 3 10
 8, permuted p , 0.0001, T:U ¼ 129:55) in our lupus
cohort (Table 1). There was also a trend for under trans-
mission of the HLA-DRB1*0701 allele (nominal p ¼ 0.0013,
T:U 42:77); however, this association was no longer signiﬁcant
after correction for multiple testing as determined by 10,000
permutations of the dataset (permuted p ¼ 0.09). Further-
more, we did not ﬁnd evidence of association with HLA-
DRB1*1501 (nominal p ¼ 1.0, T:U 70:70) or HLA-DRB1*0801
(nominal p¼1.0, T:U¼11:11) in our cohort (see Table S2 for
complete HLA-DRB1 association data); alleles previously
suggested by microsatellite typing of a US lupus cohort [25].
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Author Summary
Systemic lupus erythematosus (SLE/lupus) is a complex autoimmune
disease in which the body’s immune system attacks its own tissues,
causing inflammation in a variety of different organs such as the
skin, joints, and kidneys. The cause of lupus is not known, but genes
play a significant role in the predisposition to disease. The major
histocompatibility complex (MHC) on Chromosome 6 contains at
least 100 different genes that affect the immune system, including
the genes with the strongest effect on lupus susceptibility. Despite
the importance of the MHC in SLE, the identity of the actual genes in
the MHC region that cause SLE has remained elusive. In the present
study, we used the latest set of genetic markers present at the MHC
in lupus families to identify the actual genes that affect the disease.
To our knowledge, we have shown for the first time that two
separate groups of genes are involved in SLE. One group of genes
alters how the immune system may inappropriately target its own
tissues in the disease. How the second set of genes predisposes to
SLE is the subject of ongoing study.Association testing of the MHC region SNPs also identiﬁed
signiﬁcant evidence of association to SLE (Table 1 for
associated markers and Table S3 for all MHC SNPs). The
SNP with the most signiﬁcant association, rs419788 (nominal
p¼4.3310
 8, permuted p , 0.0001) was of similar strength to
that of the HLA-DRB1*0301 allele, with odds ratios (ORs) and
95% conﬁdence intervals (CIs) of 2.0 (1.6–2.6) and 2.3 (1.7–
3.2), respectively. This SNP is located within intron 6 of the
class III gene, superkiller viralicidic activity 2-like (Saccha-
romyces cerevisiae)( SKIV2L), and is located approximately 500
kb telomeric to the HLA-DRB1 gene. Of the other 12 SNPs
that were signiﬁcantly associated with SLE (nominal p¼4.03
10
 4 to 2.5 3 10
 7; permuted p ¼ 0.03 to ,0.0001), one was
located in the class I region between HLA-B and MICA, seven
were located in the class III region, and four were situated in
the class II region (Table 1; Figure S1). Speciﬁcally, the seven
associated class III SNPs were located in or close to the
following genes: the TNF promoter, BAT3, SLC44A4, EHMT2,
TNXB, GPSM3, and NOTCH4. One of the four class II
associated SNPs was close to HLA-DRA, two were between
HLA-DRB1 and HLA-DQA1 and one was in intron 1 of HLA-
DQA1. The correlation between all 68 SNPs and HLA-DRB1 in
our UK SLE cohort is illustrated in Figure 1. The markers
showing signiﬁcant association are highlighted.
Conditional Analyses Identify Two Independent
Association Signals in the MHC
In order to establish whether the two most associated
signals identiﬁed in this association-mapping experiment are
likely to represent a single causal allele or independent risk
factors, we ﬁrst examined the association data conditioned
upon the presence of the HLA-DRB1*0301 allele. We found
that four of the 13 associated SNPs showed evidence of signals
independent of HLA-DRB1*0301 in our dataset, the strongest
of which was rs419788 (Table 1). We therefore conditioned
the three remaining SNPs (rs2523589, rs1052486,a n d
rs605203)o nrs419788 to assess whether these signals are
truly independent of each other or show association due to
LD with rs419788. In addition, we included HLA-DRB1 in
stepwise conditional regression analyses performed on the
SNPs showing association independent of HLA-DRB1 (un-
published data). These analyses demonstrated that the
observed association signals at rs2523589, rs1052486, and
rs605203 were predominantly dependent upon the associa-
tion at rs419788, and suggested that there are two major
independent association signals in the MHC in UK SLE: HLA-
DRB1 and rs419788. The independence of the association
signals at HLA-DRB1 and rs419788 is further supported by the
observation that there is only modest LD between these two
(r
2 ¼ 0.24). There was no association with any other HLA-
DRB1 allele and the four SNPs independent of HLA-
DRB1*0301 (TRANSMIT, unpublished data).
The association of the tumour necrosis factor gene
promoter SNP TNF-308G/A with SLE is lost after conditioning
for HLA-DRB1*0301 in our cohort. If we perform the reverse
analysis and condition HLA-DRB1*0301 on the presence of
the TNF promoter SNP, we ﬁnd that the association remains,
conﬁrming that our TNF association is secondary to that of
HLA-DRB1*0301.
Genotypic Risk for Class II and Class III Association Signals
Having established independent association at the allelic
level with HLA-DRB1*0301 and rs419788-T in our UK SLE
cohort, we wanted to further determine the genotypic risk
conferred by these variants and hence gain insight into their
underlying mode of inheritance in lupus. We used case-
control and family-based analyses to assess genotypic risk at
HLA-DRB1, while the family-based test alone was used for
Table 1. Single Marker Association and Conditional Regression Analysis in 314 UK SLE Trios
Marker
#
Marker Location MAF Minor
Allele
Associated
Allele
Single Marker Association Conditional Analysis
T:U Nominal
p Value
Permuted
p Value
a
OR
(95% CI)
DRB1*0301
p Value
rs419788
p Value
3 rs2523589 Intergenic HLA-B and MICA 0.46 T G 179:107 2.1 3 10
 5 0.002 1.7 (1.3–2.1) 0.030 0.07
12 rs1800629 TNF promoter 0.25 T T 139:85 3.0 3 10
 4 0.020 1.6 (1.2–2.1) 0.200
14 rs1052486 BAT3 exon 14
nonsynonymous
0.41 G A 159:92 2.4 3 10
 5 0.002 1.7 (1.3–2.2) 0.030 0.40
21 rs605203 59 SLC44A4 0.39 C C 163:95 2.3 3 10
 5 0.002 1.7 (1.3–2.2) 0.030 0.70
22 rs589428 EHMT2 intron 27 0.39 T T 172:107 1.0 3 10
 4 0.007 1.6 (1.3–2.0) 0.060
23 rs419788 SKIV2L intron 6 0.37 T T 180:90 4.3 3 10
 8 ,0.0001 2.0 (1.6–2.6) 0.001 N/A
25 rs433061 TNXB intron 31 0.18 A A 110:47 5.0 3 10
 7 ,0.0001 2.3 (1.7–3.3) 0.200
27 rs204989 GPSM3 intron 3 0.26 A A 140:78 2.7 3 10
 5 0.002 1.8 (1.4–2.4) 0.100
29 rs3131296 NOTCH4 intron 18 0.21 T T 150:73 2.5 3 10
 7 ,0.0001 2.1 (1.6–2.7) 0.600
45 rs2227139 intergenic HLA-DRA and
HLA-DRB9
0.46 G G 145:91 4.0 3 10
 4 0.030 1.6 (1.2–2.1) 0.500
48 HLA_DRB1_0301 HLA-DRB1 0.21 A A 129:55 4.9 3 10
 8 ,0.0001 2.3 (1.7–3.2) N/A 0.0008
49 rs3129763 intergenic HLA-DRB1 and
HLA-DQA1
0.28 T T 145:77 5.0 3 10
 6 0.0002 1.8 (1.4–2.5) 0.300
50 rs2040406 intergenic HLA-DRB1 and
HLA-DQA1
0.23 G G 112:59 5.0 3 10
 5 0.003 1.9 (1.4–2.6) 0.050
51 rs2187668 HLA-DQA1 intron 1 0.21 T T 132:65 1.8 3 10
 6 0.0002 2.0 (1.5–2.7) N/A
b
a10 000 permutations in Haploview.
b HLA-DRB1*0301 tag SNP.
MAF, minor allele frequency; N/A, not applicable.
doi:10.1371/journal.pgen.0030192.t001
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The MHC and SLErs419788. Common family-based tests of LD, such as those
used in this study (Genehunter), measure transmission
distortion based on allele counts rather than genotype
counts; the former has been shown to be more powerful
under additive models, while the latter has greater power
under recessive or dominant genetic models [27]. The
genotype-pedigree disequilibrium test (geno-PDT) deter-
mines LD between a locus genotype and disease by compar-
ing genotypes that are transmitted from parent to proband
with those that are not [27]. We used the geno-PDT to assess
genotypic risk for our class II and class III association signals:
HLA-DRB1 and the SNP rs419788. In the case-control analysis
for HLA-DRB1, ORs with 95% CI were calculated and Fisher’s
exact test employed to assess statistically signiﬁcant differ-
ences between HLA-DRB1 genotypes in lupus probands and
healthy controls. For HLA-DRB1, the alleles were coded as
follows: HLA-DRB1*0301, HLA-DRB1*1501, HLA-DRB1*X
where X represents all HLA-DRB1 alleles other than HLA-
DRB1*0301,a n dHLA-DRB1*1501. We included HLA-
DRB1*1501 in the analysis, even though we ﬁnd no allelic
association in our cohort, because previous studies have
shown a greater risk for lupus in individuals who are
compound heterozygotes for HLA-DRB1*0301- and HLA-
DRB1*1501-containing haplotypes [25,28]. Overall the results
are consistent with a dominant effect from HLA-DRB1*0301
(Table 2) and a dose-dependent (additive) effect from
rs419788-T (Table 3). Speciﬁcally, both case-control and
geno-PDT demonstrate that there is no dose-dependent
increase in disease risk for HLA-DRB1*0301.R a t h e r ,i t
appears that the presence of a single copy of HLA-
DRB1*0301 alone is sufﬁcient to increase susceptibility to
disease. Moreover the 0301/X genotypes constitute the great-
est risk in our cohort rather than the 0301/1501 hetero-
zygotes. Genotypes containing HLA-DRB1*1501 in the
absence of HLA-DRB1*0301 revealed no signiﬁcant associa-
tion in our cohort.
All three rs419788 genotypes demonstrated signiﬁcant
association in our lupus families (Table 3). The common CC
Figure 1. LD Plot of All 69 MHC Markers Typed in 314 UK SLE Trios
The figure illustrates the correlation between all 69 MHC markers successfully typed across 2.4 Mb of genome encompassing MHC class II and class III in
314 UK SLE trios. The markers are identified by rs numbers for the 68 SNPs while HLA_DRB1 indicates all HLA-DRB1 alleles coded as a biallelic marker:
HLA-DRB1*0301/non-HLA-DRB1*0301. The numbers shown below the marker names correspond to the marker numbering in Tables 1, S1, and S3 for
ease of interpretation. The grey ticks indicate SNP location to scale. The triangular units designate haplotype blocks. The open rectangles represent the
14 markers that show significant association in the cohort after permutation testing; the green rectangle highlights our class III signal, SNP rs419788; and
the red rectangle designates our class II signal, HLA-DRB1. The 53 markers used for the EHH analyses and haplotype bifurcation plots are designated by
open squares. The degree of correlation between pairs of markers is indicated by the correlation coefficient r
2 (where r
2¼0¼no correlation, white; 0 ,
r
2 , 1, shades of grey; r
2 ¼ 1 ¼ complete correlation, black).
doi:10.1371/journal.pgen.0030192.g001
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The MHC and SLEgenotype was signiﬁcantly under transmitted, while the rare T
allele displayed dose-dependent over transmission to lupus
probands.
Characterization of HLA-DRB1*0301 Risk Haplotype
Next, we wanted to further delimit the MHC class II
association signal that we have detected at HLA-DRB1.W e
used phased parental genotype data to compare the allelic
composition of HLA-DRB1*0301-bearing haplotypes that
were transmitted (T) to affected probands to those that were
not transmitted (or untransmitted, UT) with the aim of
identifying differences that could delineate the lupus
susceptibility interval(s) arising from this haplotype (sum-
marized in Figures 2A, 2B, and S2). We observed a striking
difference between transmitted and untransmitted chromo-
somes within the class II region: nearly all transmitted HLA-
DRB1*0301 haplotypes (99%) are identical across a 180 kb
region deﬁned by eight SNPs, whereas the corresponding
region within untransmitted HLA-DRB1*0301 haplotypes
exhibits signiﬁcant recombination. These data strongly
suggest the existence of a risk haplotype that, interestingly,
contains only three expressed genes: HLA-DRB1, HLA-DQA1,
and HLA-DQB1. Furthermore, we can conﬁdently deﬁne the
allelic composition of this risk haplotype, as these three genes
are in strong LD and occur in one common haplotype in
Caucasians: HLA-DRB1*0301-HLA-DQA1*0501-HLA-
DQB1*0201. Thus, we hypothesize that the speciﬁc combina-
tion of all three alleles is required to confer disease risk in
lupus or that disease susceptibility lies with either HLA-
DRB1*0301 or the HLA-DQ alleles. We do not have sufﬁcient
numbers of recombinant chromosomes in this risk region to
further delimit this signal: 2/176 (1.1%) transmitted HLA-
DRB1*0301 haplotypes are recombinant at HLA-DQA1-HLA-
DQB1; 3/178 (1.7%) transmitted haplotypes identical across
HLA-DQA1-HLA-DQB1 do not possess HLA-DRB1*0301.
The composite relative extended haplotype homozygosity
(REHH) versus frequency plot for UK SLE; Utah residents
with ancestry from northern and western Europe (CEPH);
and Yoruba in Ibadan, Nigeria (Yoruba) populations is shown
in Figure 3A. We can only comment on evidence for positive
s e l e c t i o ni nC E P Hi n d i v i d u a l s ,a sw eh a v eu s e dt h i s
population alone to assess background variation on Chro-
mosome 6. The SLE and Yoruba cohorts are shown for
comparative purposes. We ﬁnd no evidence of positive
selection for HLA-DRB1*0301 in the CEPH population.
However, this allele is enriched in our lupus cohort (21% of
parental chromosomes) and displays greater extended homo-
zygosity when compared with HLA-DRB1*0301-bearing hap-
lotypes in CEPH and Yoruba. Hence, the HLA-DRB1*0301
allele in lupus is observed as an outlier on the plot when
compared to background variation in CEPH. These data
support our previous observations (outlined above) of the
highly conserved nature of HLA-DRB1*0301 haplotypes in
lupus. In addition, the haplotype bifurcation plots centered
on HLA-DRB1*0301 for UK SLE, CEPH, and Yoruba
populations in Figure 3B illustrate preservation of the
common HLA-DRB1*0301 haplotype in CEPH and UK SLE,
while that seen in the Yoruba is signiﬁcantly different. The
class II regions of all three populations are essentially
identical across our chosen SNPs; the main differences lie
in class III. The difference in African populations in the class
III region is one possible explanation for the lack of evidence
for an association between HLA-DRB1*0301 and SLE in
African or African American populations. However, HLA-
DRB1*0301 has a lower frequency (;7%–10%) in African
populations compared with Europeans (;13%), and the
number of HLA association studies conducted in African
populations is very limited.
Characterization of Class III Region Risk Haplotype
Our data reveal a second independent signal at the MHC in
SLE arising from the T allele of SNP rs419788 in intron 6 of
the class III gene, SKIV2L. Further evidence supporting the
independence of the rs419788-T and HLA-DRB1*0301 alleles
is provided by the moderate LD between these two variants
(r
2 ¼ 0.24) coupled with our data demonstrating that only
47% of rs419788-T allele-bearing haplotypes contain HLA-
DRB1*0301.
The structure and composition of T and UT haplotypes
anchored at rs419788-T were essentially identical (Figures 2C,
2D, and S2), and hence not informative in delimiting our class
III signal. Therefore, we examined the LD structure around
our associated class III SNP to better deﬁne our disease risk
interval. In our lupus dataset the rs419788-T allele resides on
three of seven haplotypes present within a large block of six
SNPs exhibiting strong LD. This haplotype block encom-
Table 3. Genotype-Pedigree Disequilibrium Test for SNP
rs419788 in 281 UK SLE Trios
Genotype T UT T:UT Z Score p Value
C/C 83 142 0.6  5.2 2.5 3 10
 7
C/T 138 110 1.3 2.4 0.016
T/T 60 29 2.1 3.5 0.0001
Data from 281 complete unrelated UK SLE trios corresponding to a total of 562
transmitted and untransmitted genotypes.
doi:10.1371/journal.pgen.0030192.t003
Table 2. Case-Control and Family-Based Genotypic Risk for HLA-
DRB1 in UK SLE Trios
Genotype Case-Control Analysis
a Genotype-PDT
b
OR 95%
CI
Fisher’s
p Value
T UT T:UT Z
Score
p Value
1501/1501 1.3 0.6–2.9 0.5 7 5 1.4 0.6 0.6
1501/X 1.2 0.9–1.7 0.2 42 56 0.8  1.6 0.1
1501/X þ
0301
1.5 1.1–2.0 0.009 65 69 0.9  0.4 0.7
0301/1501 1.9 1.2–3.0 0.009 23 13 1.8 1.8 0.08
0301/0301 2.6 1.5–4.5 0.001 17 11 1.5 1.1 0.26
0301/X 2.9 2.2–3.8 ,0.0001 91 39 2.3 5.0 7.1 3 10
 7
0301/X þ
1501
3.0 2.3–3.9 ,0.0001 114 52 2.2 5.5 3.3 3 10
 8
X/X 0.3 0.2–0.4 ,0.0001 87 143 0.6  4.7 2.6 3 10
 6
aData from 296 unrelated UK SLE cases and 1,667 unrelated healthy male controls.
bData from 267 unrelated complete UK SLE trios corresponding to a total of 534
transmitted and untransmitted genotypes.
1501¼HLA-DRB1*1501, 1502, 1504, and 1506 (the majority of alleles are 1501) in controls
and 1501 ¼ HLA-DRB1*1501 and1502 in UK SLE, 0301 ¼ HLA-DRB1*0301, X is any DRB1
allele other than 0301 or 1501.
doi:10.1371/journal.pgen.0030192.t002
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The MHC and SLEFigure 2. Structure of Transmitted and Untransmitted HLA-DRB1*0301 and rs419788-T Allele Haplotypes
Haplotype bifurcation plots were constructed using 120 randomly selected parental chromosomes from each of the four datasets for comparative
purposes except (B),where there were only 90 chromosomes in the entire dataset: (A) T HLA-DRB1*0301 haplotypes, (B) UT HLA-DRB1*0301 haplotypes,
(C) T rs419788-T allele haplotypes, and (D) UT rs419788-T allele haplotypes. The allelic composition of the most common haplotype in each subset is
shown: the core allele is represented as a dark blue double bar indicating haplotypes to the right and to the left of the core; otherwise, the common
haplotype is depicted by dark grey bars. In parts (A) and (B), the rs419788-T allele in class III that shows association independent of HLA-DRB1*0301 in
our cohort is indicated in green, while in parts (C) and (D), the allele HLA-DRB1*0301 is shown in green. The key difference between HLA-DRB1*0301 T
and UT haplotypes lies within the class II region of the MHC. All HLA-DRB1*0301 T haplotypes are identical across a 180 kb region defined by eight SNPs
(light blue), whereas the corresponding region within UT HLA-DRB1*0301 haplotypes exhibits significant recombination. This conserved class II interval
encompasses only three expressed genes: HLA-DRB1, HLA-DQA1, and HLA-DQB1. Given the strong LD exhibited by HLA-DRB1*0301 haplotypes, the allelic
composition of this risk region is known to be HLA-DRB1*0301-HLA-DQA1*0501-HLA-DQB1*0201. Both T and UT rs419788-T allele haplotypes show
similar structure overall. The rs419788-T allele is clearly present on HLA-DRB1*0301 and non-HLA-DRB1*0301-containing haplotypes, lending credence to
our observation that rs419788-T or another variant in LD with it constitutes an association signal independent of HLA-DRB1*0301 in our UK SLE cohort.
(A) 120 from a total of 176 parental chromosomes, (B) 90 from a total of 90 parental chromosomes, (C) 120 from a total of 284 parental chromosomes,
and (D) 120 from a total of 182 parental chromosomes.
doi:10.1371/journal.pgen.0030192.g002
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The MHC and SLEpasses roughly 270 kb containing class III genes from
SLC44A4 to AGER, including the RCCX module. Next, we
analyzed the haplotype block structure of this region in
CEPH families using SNP data dumped from the Interna-
tional HapMap Project (http://www.hapmap.org/). The greater
density of SNP typing available in the HapMap CEPH
population compared to our current UK SLE map allowed
us to potentially reﬁne our signal by exploring correlations
between our associated SNP and those surrounding it.
Analysis of these data (Figure 4) suggests the presence of
short-range LD around our associated variant, rs419788,i n
CEPH families, encompassing approximately 40 kb of the
genome which includes the ﬁve genes: complement factor B
(CFB), RD RNA binding protein (RDBP), SKIV2L, dom-3
Figure 3. REHH versus Frequency Analysis and Comparison of HLA-DRB1*0301 Haplotype Bifurcation Plots in UK SLE, CEPH, and Yoruba Populations
(A) Composite REHH versus frequency analysis comparing CEPH with UK SLE and Yoruba populations generated in SWEEP. REHH is shown on the
vertical axis and haplotype frequency on the horizontal axis. Background CEPH genotype data for Chromosome 6 is indicated by grey data points; the
53 SNPs common to the UK SLE, CEPH, and Yoruba datasets are shown as red, blue, and turquoise data points, respectively. The 95th percentile for
background variation in CEPH is indicated. The position of the HLA-DRB1*0301 allele is shown in all three cohorts (a, b, and c). The alleles rs2187668-T
(HLA-DRB1*0301 tag SNP in UK SLE) (d) and HLA-DRB1*0301 in UK SLE are the only core markers observed above the 95th percentile. The associated
class III SNP, rs419788-T, is also indicated (e). We can only examine evidence for positive selection in CEPH, as these are the data we have used to assess
background variation. There is no evidence for positive selection of the HLA-DRB1*0301 allele in CEPH. This allele is enriched in our lupus cohort (21% of
parental chromosomes), and displays greater extended homozygosity when compared with HLA-DRB1*0301-bearing haplotypes in CEPH and Yoruba.
(B) Comparison of HLA-DRB1*0301 haplotype bifurcation plots for (i) UK SLE, (ii) CEPH, and (iii) Yoruba populations. We show preservation of the
common HLA-DRB1*0301 haplotype in CEPH and UK SLE, while that seen in the Yoruba is significantly different (differences indicated in yellow, core
allele shown in dark blue). The class II regions of all three populations are essentially identical across our chosen SNPs; the main differences lie in class III.
120 (of 1,256) randomly selected transmitted and untransmitted parental UK SLE chromosomes used for haplotype bifurcation plot for comparison with
120 total CEPH and 120 total Yoruba chromosomes.
doi:10.1371/journal.pgen.0030192.g003
Figure 4. LD Plot of HapMap CEPH Data Centered on the Associated Class III SNP rs419788
One hundred and twenty kilobases of the MHC class III region centered on rs419788 (boxed) in HapMap CEPH families is illustrated. The grey ticks
indicate SNP location with gene location shown above and rs numbers below. The triangular units designate haplotype blocks. The degree of
correlation (LD) between pairs of markers is indicated by the correlation coefficient r
2 (where r2¼0¼no correlation, white; 0 , r
2 , 1, shades of grey; r
2
¼ 1 ¼ complete correlation, black). The dashed arrows depict LD between rs419788 and surrounding SNPs. Significant LD (r
2 . 0.8) is observed with
rs419788 and three further SNPs within SKIV2L, two SNPs in STK19, and one SNP in CFB.
doi:10.1371/journal.pgen.0030192.g004
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The MHC and SLEhomolg Z (C. elegans) (DOM3Z), and serine/threonine kinase
19 (STK19), and does not include the complement C4 locus.
Furthermore, assessment of marker association in our lupus
dataset demonstrates that after conditioning for HLA-
DRB1*0301, the only markers that retain association signals
are telomeric of SKIV2L, suggesting that complement C4,
which is centromeric to this gene, may not be responsible for
our independent class III signal.
Subphenotype Analysis
In order to gain further insight into disease pathogenesis,
we examined common lupus subphenotypes. Such subsets are
more homogeneous than lupus per se and thus maybe
enriched for speciﬁc predisposing variants. In addition, one
might expect a close association between MHC class II alleles
and autoantibody subsets in lupus if these are indeed causal
variants, given their role in antigen presentation and
subsequent humoral immunity. We therefore tested our two
main MHC association signals, HLA-DRB1*0301 and
rs419788, for association with renal disease and autoantibody
subsets in our lupus cohort.
We found that HLA-DRB1*0301 was associated with the
presence of anti-Ro and anti-La antibodies in our UK SLE
cohort, with the latter showing the greatest evidence of
association (anti-La nominal p , 0.001 compared with anti-
Ro nominal p , 0.025). We found no association of HLA-
DRB1*0301 with renal disease or any other autoantibody
subsets in our dataset (see Table S4 for detailed results).
Genotypes of the SNP rs419788 were not associated with
any of the tested lupus subphenotypes after controlling for
the effect of HLA-DRB1*0301 (unpublished data).
Discussion
We present the ﬁrst family-based SNP association study of
the MHC in SLE. We have genotyped 69 markers (HLA-DRB1
and 68 SNPs) across 2.4 Mb of the MHC, encompassing class
III and class II, in a cohort of 314 UK Caucasian SLE trios.
Transmission disequilibrium testing of these data has shown
predominant association with the alleles HLA-DRB1*0301
and rs419788-T, together with 12 other MHC SNPs. Moreover,
using conditional analyses, we have shown that the two
primary signals of association at the MHC are independent of
each other. Speciﬁcally, one signal arises from HLA-
DRB1*0301 in class II and the other from the T allele of
SNP rs419788 in the class III gene SKIV2L.
Examination of bifurcation plots for T and UT HLA-
DRB1*0301-containing haplotypes has enabled delineation of
our class II association signal to a 180 kb region encompass-
ing HLA-DRB1*0301-HLA-DQA1*0501-HLA-DQB1*0201.
These data substantially reﬁne that previously published by
Graham et al. in 2002 [25], where the lupus susceptibility
interval within HLA-DRB1*0301-containing haplotypes could
only be delimited to a 1 Mb region encompassing class II and
class III. The precise causal variant(s) within this region
remains to be determined, as the three implicated alleles
exhibit strong LD with few recombination events separating
them (two out of 176 transmitted HLA-DRB1*0301 chromo-
somes in our dataset). However, all three allelic variants
represent attractive functional candidates in lupus suscept-
ibility for their role in antigen presentation and stimulation
of the adaptive immune response.
Our association of HLA-DRB1*0301 with lupus concurs
with published data in Caucasian cohorts and is well
established [16]. While our lack of association with HLA-
DRB1*1501 and HLA-DRB1*0801 is consistent with previous
data from the UK [29], Spain [30], the Netherlands [31],
Sweden [32], Mexico [33], and the US [34], it conﬂicts with
that of other US groups [25,35]. Interestingly, we demonstrate
a trend, though not statistically signiﬁcant, for undertrans-
mission of HLA-DRB1*0701—a result also observed in prior
UK and Canadian lupus studies [29,36]. Moreover, a negative
association of HLA-DRB1*0701 has been reported in other
autoimmune diseases including Graves disease [37,38], type 1
diabetes [39], and rheumatoid arthritis [40].
It appears that the conﬂicting results between UK SLE and
previous US (Minnesota [MN]) [25] SLE data stem from
differences in HLA-DRB1 allele frequency in the probands of
each cohort. The reason for this is unclear. A comparison
between UK and MN SLE cohorts (Table 4) reveals that UK
SLE cases are enriched for HLA-DRB1*0301 but not HLA-
DRB1*0801 or HLA-DRB1*1501 when compared to a UK
control population. In contrast, MN SLE cases are enriched
for HLA-DRB1*0301-DQB1*0201, DRB1*0801-DQB1*0402,
and DRB1*1501-DQB1*0602 inferred haplotypes when com-
pared to MN controls [25]. There is no statistically signiﬁcant
difference in the aforementioned HLA class II alleles/
haplotypes between UK and MN control populations that
could account for the disparity seen in the respective lupus
Table 4. Comparison of HLA-DRB1 Allele/Haplotype Frequencies in UK SLE and US (Minnesota) SLE Cohorts
UK SLE
Experimental
HLA-DRB1 Allele
UK SLE
a Allele
Frequency (%)
UK
b Control Allele
Frequency (%)
MNSLE Inferred
HLA-DRB1-DQB1
Haplotype
MNSLE
c Haplotype
Frequency (%)
MN
c Control Haplotype
Frequency (%)
MN
b Control Allele
Frequency (%)
(n ¼588) (n ¼ 354) (n ¼ 566) (n ¼ 1,804) (n ¼ 678)
HLA-DRB1 HLA-DRB1-DQB1 HLA-DRB1
0301 27.7 12.7 0301–0201 17.3 9.8 13.7
0801 2.2 2.0 0801–0402 3.2 2.2 3.2
1501 14.4 14.7 1501–0602 21.8 14.2 12.4
aSource: current publication.
bSource: http://www.allelefrequencies.net.
cSource: [25].
MN, Minnesota; n, number of chromosomes.
doi:10.1371/journal.pgen.0030192.t004
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frequency between the two populations could account for the
observed discrepancy. From the limited data available we
found that the presence of renal disease appears to be similar
in both cohorts (UK SLE 36% compared with MN SLE 40%),
while the gender ratios are signiﬁcantly different (female:
male UK SLE 11:1 compared with MN SLE 57:1, Chi square p
value , 0.001). We were unable to compare other lupus
subphenotypes. Furthermore, closer inspection of these data
reveals that microsatellite-inference of HLA-DRB1 alleles in
the MN SLE dataset may underestimate the frequency of
HLA-DRB1*0301 and overestimate that of HLA-DRB1*1501,
thus diminishing the effect of the former and enhancing that
of the latter. It is also possible that the MN SLE cohort shows
greater racial heterogeneity in comparison to our UK SLE
cohort, despite both being characterized as Caucasian.
Previous studies have demonstrated increased risk for
lupus in individuals carrying particular combinations of
microsatellite-inferred HLA-DRB1-HLA-DQB1 haplotypes
[25,28]. The highest risk genotype was found to be the
compound heterozygote HLA-DRB1*0301-DQB1*0201/HLA-
DRB1*1501-DQB1*0602, while HLA-DRB1*0301-DQB1*0201-
containing genotypes demonstrated a dose-dependent effect
in increasing lupus susceptibility [25,28]. In the present study,
we have examined genotypic risk at the classically typed HLA-
DRB1 locus and in contrast to the aforementioned data of
Graham et al. [25,28] we have shown a likely dominant effect
of the associated allele, HLA-DRB1*0301. The case-control
and family-based analyses for HLA-DRB1 also show the
greater power of the former to detect signiﬁcant association
(Table 2). Speciﬁcally, all genotypes containing HLA-
DRB1*0301 show increased transmission to lupus probands;
however, homozygotes show no greater risk compared with
heterozygotes, as would be expected under additive or
multiplicative models. Thus, a dominant model of inheri-
tance, requiring the presence of a single copy of the disease-
predisposing variant alone, likely underlies the susceptibility
conferred by HLA-DRB1*0301 in UK SLE. Such a model
would ﬁt an antigen presentation hypothesis where suscep-
tible individuals carrying an HLA-DRB1*0301 allele are able
to present auto-antigens to CD4þlymphocytes, thus stimulat-
ing an autoimmune response. The differences between our
UK SLE and the previously published US SLE data may reﬂect
disease, ethnic, and haplotypic heterogeneity.
Interestingly, analysis of genotypic risk at the associated
class III marker, rs419788, suggests an additive (dose-depend-
ent) pattern of inheritance for the rare T allele, where one
copy confers a low risk of disease and two copies results in
greater susceptibility. The different inheritance patterns for
our class II and class III association signals provide further
evidence for their independence.
Av a r i e t yo fHLA-DR and HLA-DQ alleles have been
associated with autoantibody subsets in ethnically diverse
populations of lupus. The strongest associations have been
demonstrated between anti-Ro and anti-La antibodies and
HLA-DR3 and HLA-DQ2 (HLA-DQB1*0201), which are in
strong LD [41–45] in case-control studies. Here, we conﬁrm
the association of HLA-DRB1*0301 with anti-Ro and anti-La
antibody production in our family-based cohort.
Examination of LD structure around our second inde-
pendent association, rs419788-T in class III, coupled with the
results of our conditional analysis, suggests that this signal
could also be delimited to a relatively narrow genomic
interval of about 40 kb given further SNP mapping in our
cohort. This region includes the genes CFB, RDBP, SKIV2L,
DOM3Z, and STK19, but does not include complement C4.
Thus, complement C4 null alleles, which have been implicated
in lupus pathogenesis, may not be responsible for our class III
signal. We conclude, therefore, that our family-based map-
ping study has potentially revealed a hitherto unknown lupus
susceptibility interval in the class III region of the MHC.
However, we cannot conclusively exclude association at
complement C4/RCCX without direct determination of C4
polymorphism/copy number in our cohort.
With respect to the genes implicated in our study, CFB is a
vital component of the alternate complement pathway and
disregulation may clearly affect the inﬂammatory response
[46]. RD and Skiv2l are proteins potentially involved in RNA
processing. The RD protein forms part of a negative
elongation factor (NELF) complex that represses RNA
polymerase II transcript elongation, while Skiv2l is a DEAD
box protein with possible function as an RNA helicase. The
function of Dom3z is currently unknown, although the
homologous yeast protein binds nuclear exoribonuclease.
Moreover, its ubiquitous expression suggests a housekeeping
role. STK19 is a protein kinase of unknown function with
primary nuclear localization [47]. Interestingly, RDBP and
SKIV2L are found to be highly expressed in T lymphocytes, B
lymphocytes, and dendritic cells (SymAtlas, http://symatlas.
gnf.org/SymAtlas/).
A number of studies have demonstrated conﬂicting
evidence for and against association with various TNF locus
polymorphisms in SLE [48]. A recent meta-analysis of the
TNF-308G/A promoter polymorphism in SLE [48] revealed
evidence of association for the minor allele (A) in European
populations; however, this study did not account for LD with
class II alleles. On conditioning our dataset for HLA-
DRB1*0301, we ﬁnd that the TNF promoter signal is lost,
suggesting that this association is not independent and is due
to LD with HLA-DRB1*0301 (or another variant in LD with
HLA-DRB1*0301).
In summary, we have found association with two distinct
and independent variants within the class II (HLA-
DRB1*0301) and class III (SKIV2L) regions of the MHC in
UK SLE trios. We can delimit our class II signal in lupus to
three genetic variants (HLA-DRB1*0301-HLA-DQA1*0501-
HLA-DQB1*0201) that may confer disease risk in combination
or as separate signals. Our class III signal importantly
excludes independent association at the TNF promoter
polymorphism TNF-308G/A and potentially provides a novel
locus for further study.
Materials and Methods
Study cohorts. SLE families. The cohort comprises 314 complete
SLE trios (that is, mother, father, and affected lupus proband)
collected as previously described [49]. All study participants are
European Caucasian on the basis of grandparental origin. All 314
lupus probands (288 female, 26 male) fulﬁll the revised American
College of Rheumatology (ACR) criteria for SLE [50], 36% of whom
have a diagnosis of lupus nephritis. Written consent was obtained
from all study participants and ethical approval for this study was
obtained from the Multi-Centre Research Ethics Committee (MREC 2
June 1998).
Healthy controls. The control population for the HLA-DRB1
genotypic risk case-control analysis constitutes 1,667 healthy males of
Northern European origin. The individuals are potential hemato-
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at the Anthony Nolan Trust, UK for this purpose. The level of
resolution used for the typing of HLA-DRB1*15 alleles in these
healthy controls resulted in the ambiguous allele string HLA-
DRB1*1501/1502/1504/1506. However, it is likely that the great
majority are HLA-DRB1*1501. There is no gender bias in HLA-
DRB1 allele frequencies, so although we have used a male control
cohort, the frequencies would be expected to be the same in a similar
female cohort (Steven Marsh, personal communication).
SNP genotyping. Eighty-six SNPs were chosen for genotyping in
our mapping study. Speciﬁcally, we selected 40 MHC class II and class
III haplotype tagging SNPs from a preliminary MHC SNP map [51]
that had previously shown robust genotyping efﬁcacy. In addition, we
typed 36 MHC class II tag SNPs from a subsequent high-resolution
MHC study [52]. We also included the TNF-308G/A promoter SNP,
together with nine further SNPs in the region of HLA-B and MICA
obtained from the database, dbSNP (http://www.ncbi.nlm.nih.gov/
projects/SNP/). The latter SNPs had not been well characterized. All
variants were typed in the entire cohort (n ¼ 942). The SNPs span
approximately 2.4 Mb of the MHC from the class I gene, KIAA1949 to
the class II pseudogene, HLA-DPB2 and thus encompass MHC class III
and class II. SNP genotyping was performed at the Broad Institute of
MIT and Harvard and at Imperial College London by matrix-assisted
laser desorption/ionisation time-of-ﬂight (MALDI-TOF) mass spec-
trometry using the Sequenom MassARRAY platform as previously
described [53]. SNPs that failed Sequenom typing were retyped by
KBiosciences (http://www.kbioscience.co.uk/) using their in-house SNP
genotyping methodology, KASPar (http://www.kbioscience.co.uk/
genotyping/index.htm), a competitive allele-speciﬁc PCR technique.
HLA-DRB1 genotyping. HLA-DRB1 typing was performed at the
Anthony Nolan Trust, UK. All samples (n ¼ 942 UK SLE trios and n ¼
1,667 controls) were genotyped using LABType SSO (sequence-speciﬁc
oligonucleotide) typing technology according to the manufacturer’s
written recommendations (http://www.onelambda.com). Brieﬂy, a lo-
cus-speciﬁc biotinylated PCR amplicon is produced, denatured, and
rehybridized to complementary oligonucleotide probes conjugated to
ﬂuorescently coded beads. The bound biotinylated PCR product can be
detected using R-phycoerythrin-conjugated streptavidin. A ﬂow
analyzer identiﬁes the ﬂuorescent intensity of phycoerythrin on each
bead. The assignment of HLA type is based on the reaction pattern
compared to patterns associated with known sequences.
High resolution testing was performed using the Dynal AllSet
þSSP
(sequence-speciﬁc primers) DRB1 assay according to the manufac-
turer’s protocol (Invitrogen) for SLE families only. The presence or
absence of PCR ampliﬁcation was detected in a gel electrophoresis
step using visualization by ethidium bromide incorporation. Geno-
types were determined using SSPTool software.
Samples that could not be resolved to four digits using SSO and
PCR-SSP were analyzed by DNA sequencing of exon 2 of HLA-DRB1.
Primers, reagents, and protocols were provided by The Anthony
Nolan Trust, UK (primer sequences are available on request). Speciﬁc
HLA-DRB1 alleles were assigned by comparing the resultant sequence
with reference sequence from the IMGT/HLA Database [54].
Data analysis. Mendelian inconsistencies were removed using
PedCheck [55]. Families in which more than eight markers
demonstrated Mendel errors were removed from further analysis.
Markers with less than 80% genotyping efﬁciency and markers where
more than eight families showed Mendel errors were also excluded
from analysis. Two markers located within the SLE associated class II
region (rs2239802 in intron 4 of HLA-DRA and rs6457594 in the
region between HLA-DRB9 and HLA-DRB5) show deviation from
Hardy–Weinberg equilibrium (HWE), which may reﬂect an unde-
tected SLE association or systematic genotyping error. HWE was
assessed in parental samples in our cohort. There is currently no
uniform opinion in the community regarding the inclusion or
exclusion of SNPs that show deviation from HWE, hence we elected
to include these markers in the ﬁnal analysis.
Sixty-eight out of the total 86 SNPs passed our quality-control
measures (see Table S1 for details). In summary, one SNP was
monomorphic in our dataset, four SNPs yielded low genotyping
efﬁciency, and 13 SNPs were excluded for unacceptable Mendel error
rate. The mean call rate for all markers post-quality control was 94%
(range 83% to 99%).
Family-based association testing was performed using Genehunter
TDT (version 2.1) [56] and TRANSMIT (version 2.5) [57]. Haplotypes
were constructed and permutation testing performed using Haplo-
view (version 3.32) [58]. Signiﬁcance of association signals in all
analyses was based on permutation testing (10,000 permutations). The
data are represented both as nominal and permuted p values. ORs
with 95% CI for family-based analyses were calculated in PLINK
(http://pngu.mgh.harvard.edu/purcell/plink/) [59]. Conditional regres-
sion analyses were undertaken using WHAP [60].
The geno-PDT was performed using PDT version 5.1 with default
settings [27]. The HLA-DRB1 alleles were coded into three groups for
the geno-PDT and the case-control analysis: HLA-DRB1*0301, HLA-
DRB1*1501 and HLA-DRX where HLA-DRX includes all HLA-DRB1
alleles other than HLA-DRB1*0301 or HLA-DRB1*1501. The HLA-
DRB1*1501 code in the healthy controls represents the allele string
HLA-DRB1*1501/1502/1504/1506, as described previously. The HLA-
DRB1*1501 code in the lupus probands represents the alleles HLA-
DRB1*1501 (84 out of 91 *1501 and *1502 alleles) and HLA-
DRB1*1502 (7/91 *1501 and *1502 alleles), as *1504 and *1506 were
not present in this population. Fisher’s exact test was used to assess
signiﬁcance of association in the case-control analysis.
Subphenotype analysis. We looked for association of the HLA-
DRB1*0301 allele with autoantibody subsets and renal disease in our
cohort using the Chi-square test. We compared cases with and
without the subphenotype of interest with DRB1*0301 homozygosity,
heterozygosity, combined homozygosity and heterozygosity, and non-
DRB1*0301 status. We performed the same analyses for homozygous
and heterozygous genotypes of the associated SNP rs419788. The
autoantibody subsets compared were anti-C1q, IgG, and IgM anti-
cardiolipin antibodies (ACLG and ACLM), anti-Ro, anti-La, anti-RNP,
anti-Sm, and anti-dsDNA.
Delineation of associated MHC haplotypes and evidence for
positive selection. We looked for positively selected alleles in our
dataset using the long-range haplotype test as measured by extended
haplotype homozygosity (EHH), previously described by Sabeti et al.
[26]. Essentially, such an analysis allows assessment of positive
selection by mining datasets for high frequency extended haplotypes
in comparison to the other core haplotypes at a locus.
EHH is deﬁned as the probability that two randomly chosen
chromosomes carrying the core haplotype of interest will be identical
by descent (homozygosity at all SNPs) for the entire interval from the
core to a distance x. The REHH is the ratio of the EHH on the tested
core haplotype compared with the combined EHH of all the other
core haplotypes at the region excluding the tested core; as such,
REHH accounts for local variation in recombination rate while EHH
does not [26].
The program emphase was employed to assign the phase of
parental genotype data and reconstruct missing information.
Emphase is a simple phaser similar to the phaser of Excofﬁer and
Slatkin [61]. It is very fast, especially on large datasets, and sufﬁciently
accurate for most genetic applications. EHH analysis was performed
on the phased parental data using the software program SWEEP
(http://www.broad.mit.edu/mpg/sweep/index.html).
Haplotype bifurcation plots. We represent the breakdown of LD on
core haplotypes using haplotype bifurcation diagrams generated in
the program TREE [62] (also explained in [52]).
REHH versus frequency plots. Fifty-three SNPs (identiﬁed in
Figure 1) are common to our dataset and the CEPH and Yoruba
HapMap [63] populations. These three datasets, together with CEPH
SNP data for Chromosome 6 in its entirety, were used to generate
separate REHH versus frequency plots in SWEEP. The plots from the
four cohorts were combined for visual, not statistical, comparison.
Evidence for positive selection was quantitatively assessed in CEPH
individuals, as this population alone was used to assess background
variation on Chromosome 6. The UK SLE and Yoruba cohort data are
shown for comparison. The 95th percentile based on total CEPH
Chromosome 6 SNP data is shown.
Supporting Information
Figure S1. OR Plot for Associated MHC Markers in 314 UK SLE Trios
OR with 95% CI and marker name in genomic order (class I to class
II, left to right) are indicated on the vertical and horizontal axes
respectively. The greatest ORs are seen in the class III and class II
regions.
Found at doi:10.1371/journal.pgen.0030192.sg001 (42 KB PDF).
Figure S2. Structure of All Transmitted and Untransmitted HLA-
DRB1*0301 and rs419788-T Allele Haplotypes
Haplotype bifurcation plots constructed for all (A) transmitted (T)
HLA-DRB1*0301 haplotypes, (B) untransmitted (UT) HLA-
DRB1*0301 haplotypes, (C) transmitted rs419788-T allele haplotypes,
and (D) untransmitted rs419788-T allele haplotypes. The allelic
composition of the most common haplotype in each subset is shown:
the core allele is represented as a dark blue double bar indicating
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The MHC and SLEhaplotypes to the right and to the left of the core; otherwise, the
common haplotype is depicted by dark grey bars. In parts (A) and
(B), the rs419788-T allele in class III, which shows association
independent of HLA-DRB1*0301 in our cohort, is indicated in
green, while in parts (C) and (D), the allele HLA-DRB1*0301 is shown
in green. The key difference between HLA-DRB1*0301 Ta n dU T
haplotypes lies within the class II region of the MHC. All HLA-
DRB1*0301 T haplotypes are identical across a 180 kb region
deﬁned by eight SNPs (light blue), whereas the corresponding region
within UT HLA-DRB1*0301 haplotypes exhibits signiﬁcant recombi-
nation. This conserved class II interval encompasses only three
expressed genes: HLA-DRB1, HLA-DQA1,a n dHLA-DQB1. Given the
strong LD exhibited by HLA-DRB1*0301 haplotypes, the allelic
composition of this risk region is known to be HLA-DRB1*0301-
HLA-DQA1*0501-HLA-DQB1*0201. Both T and UT rs419788-T allele
haplotypes show similar structure overall. The rs419788-T allele is
clearly present on HLA-DRB1*0301 and non-HLA-DRB1*0301-
containing haplotypes, lending credence to our observation that
rs419788-T or another variant in LD with it constitutes an
association signal independent of HLA-DRB1*0301 in our UK SLE
cohort.
(A) total of 176 parental chromosomes, (B) total of 90 parental
chromosomes, (C) total of 284 parental chromosomes, and (D) total of
182 parental chromosomes.
Found at doi:10.1371/journal.pgen.0030192.sg002 (338 KB PDF).
Table S1. Quality Control Information for Four-Digit HLA-DRB1
Typing and All 86 SNPs Chosen for Genotyping in a Cohort of 314
UK SLE Trios
Found at doi:10.1371/journal.pgen.0030192.st001 (26 KB XLS).
Table S2. OR and TDT Data for Four-Digit HLA-DRB1 Typing in a
Cohort of 314 UK SLE Trios
Found at doi:10.1371/journal.pgen.0030192.st002 (20 KB XLS).
Table S3. Complete Single Marker (SNP) and HLA-DRB1*0301
Association Data in a Cohort of 314 UK SLE Trios
Found at doi:10.1371/journal.pgen.0030192.st003 (34 KB XLS).
Table S4. Association of HLA-DRB1*0301 Genotypes with SLE
Subphenotypes in 314 UK SLE Probands
Found at doi:10.1371/journal.pgen.0030192.st004 (32 KB DOC).
Accession Numbers
The Online Mendelian Inheritance in Man (OMIM, http://www.ncbi.
nlm.nih.gov/sites/entrez?db¼omim) accession numbers for the genes
described in this study are as follows: AGER, 600214; BAT3, 142590;
C4A, 120810; C4B, 120820; CFB, 138470; DOM3Z, 605996; DOM3Z,
605996; EHMT2, 604599; HLA-B, 142830; HLA-DPB2, 120290; HLA-
DQA1, 146880; HLA-DQB1, 604305; HLA-DRA, 142860; HLA-DRB1,
142857; KIAA1949, 610990; MICA, 600169; NOTCH4, 164951; RDBP,
154040; RDBP, 154040; SKIV2L, 600478; SLC44A4, 606107; STK19,
604977; STK19, 604977; TNF, 191160; and TNXB, 600985.
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